Research provided by covering analysts routinely includes opinions on the future price of the stock. This research may also include ratings and estimates in the reports. Investors have the option to track analyst projections in order to help piece together valuable information. Out of the 5 covering Wall Street analysts providing share ratings for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP), 3 have rated the stock as a Strong Buy while 1 analysts have the stock listed as a Buy. 1 analysts have a Hold rating on the stock, and 1 are giving a Sell recommendation.
These recommendations can be transferred to a standard scale from 1 to 5. Combining all of the ratings, the current consensus is sitting at 2. A rating of 1 would be equivalent to a Strong Buy, and a rating of 5 would indicate a Strong Sell rating.
Let’s take a look at analyst target price estimates on the stock. The 5 analysts offering target price estimates on shares of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) have set a consensus target of $10.4 on shares. The standard deviation of all the estimates is currently $5.029. Target price projections may differ from analyst to analyst. The lowest price target is presently $5 and the analyst with the most aggressive opinion sees the stock going to $16.
The quarterly company earnings release is usually highly anticipated. Each quarter, investors and analysts wait to see the earnings numbers when they are posted for the public. The company is slated to next publish earnings on or around N/A. The current Wall Street consensus is expecting Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to report EPS of $N/A for the quarter. Analysts often update their models during the time leading up to earnings. The sentiment direction can be an important factor when trying to gauge where the Street sees the stock moving. Compared to the same quarter last year, the company reported earnings per share of $N/A. After the most recent period, the company reported quarterly EPS of $N/A against the Zacks Research consensus estimate of $-0.24. This created a surprise factor of -25% or a numerical difference of $-0.06.
This article is for informational purposes only. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell Adaptimmune Therapeutics PLC – ADR.